Status:
COMPLETED
Use of a Remifentanil-propofol Mixture in Patients Undergoing Breast Cancer Surgery
Lead Sponsor:
Tri-Service General Hospital
Conditions:
Anesthetics
Remifentanil
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Co-administration of propofol and remifentanil is considered to be an ideal total intravenous anesthesia technique, which is widely used in induction and maintenance of general anesthesia. Remifentani...
Detailed Description
Previous studies has described the feasibility and safety of remifentanil-propofol mixture use in sedation of pediatric patients undergoing magnetic resonance imaging or flexible fiberoptic bronchosco...
Eligibility Criteria
Inclusion
- ASA II or III
- age more than 18 years
- scheduled for breast cancer surgery under general anesthesia.
Exclusion
- previously allergic to propofol or remifentanil
- combining other surgical procedure leading to extended operative time
Key Trial Info
Start Date :
August 3 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 27 2018
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT03817359
Start Date
August 3 2018
End Date
December 27 2018
Last Update
January 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tri-Service General hospital
Taipei, Taiwan, 114